Citation Report
List of articles citing

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials

DOI: 10.1007/s13300-019-00747-3
Diabetes Therapy, 2020, 11, 369-386.

#	Paper	IF	Citations
43	Diabetes and Novel Coronavirus Infection: Implications for Treatment. *Diabetes Therapy*, **2020**, 11, 1915-1924	3.6	4
42	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. *Diabetes Therapy*, **2020**, 11, 1925-1934	3.6	8
41	Insulin: Trigger and Target of Renal Functions. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 519	5.7	6
40	Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. *Diabetes Therapy*, **2020**, 11, 2221-2235	3.6	6
39	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2227-2240	6.7	8
38	Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. *Diabetes Therapy*, **2020**, 11, 2207-2219	3.6	21
37	Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations. *International Journal of General Medicine*, **2020**, 13, 1395-1409	2.3	4
36	Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection. *International Journal of Cardiology: Hypertension*, **2020**, 7, 100058	1.6	
35	Advances in the management of diabetes: therapies for type 2 diabetes. *Postgraduate Medical Journal*, **2020**, 96, 610-618	2	1
34	Exercise-induced albuminuria increases over time in individuals with impaired glucose metabolism. *Cardiovascular Diabetology*, **2020**, 19, 90	8.7	0
33	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. *Metabolism: Clinical and Experimental*, **2020**, 107, 154218	12.7	5
32	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. *Diabetes Research and Clinical Practice*, **2020**, 161, 108054	7.4	7
31	Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study. *PLoS ONE*, **2020**, 15, e0229377	3.7	3
30	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. *Diabetes Therapy*, **2020**, 11, 1199-1216	3.6	56
29	Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control. *International Journal of Clinical Practice*, **2021**, 75, e13769	2.9	1
28	Sodium-Glucose Co-Transporter‐2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. *Diabetes Therapy*, **2021**, 12, 55-70	3.6	10
27	Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. *Diabetes/Metabolism Research and Reviews*, **2021**, 37, e3416	7.5	4

26	Heterogeneity in renal end□points of cardiovascular outcomes trials in Type 2 diabetes. *Journal of Comparative Effectiveness Research*, **2021**, 10, 169-173	2.1	1
25	The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. *Pharmaceuticals*, **2021**, 14,	5.2	15
24	Sodium Intake and Proteinuria/Albuminuria in the Population-Observational, Cross-Sectional Study. *Nutrients*, **2021**, 13,	6.7	0
23	From Obesity to Chronic Kidney Disease: How Can Adipose Tissue Affect Renal Function?. *Nephron*, **2021**, 145, 609-613	3.3	5
22	Future of Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Nephropathy. *Cardiologia Croatica*, **2021**, 16, 157-163	0	
21	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. *Future Cardiology*, **2021**, 17, 459-473	1.3	2
20	Comorbidities and complications in Japanese patients with type 2 diabetes mellitus: Retrospective analyses of J-DREAMS, an advanced electronic medical records database. *Diabetes Research and Clinical Practice*, **2021**, 178, 108845	7.4	0
19	Recent therapeutic targets in diabetic nephropathy. *International Journal of Clinical Practice*, **2021**, 75, e14650	2.9	1
18	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. *European Journal of Pharmacology*, **2021**, 907, 174272	5.3	3
17	Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR. *Kidney International Reports*, **2021**, 6, 2415-2424	4.1	2
16	[Is Concomitant Therapy with Acetaminophen and Low-dose Aspirin a Risk Factor for CKD Progression? A 6-Year Cohort Study]. *Yakugaku Zasshi*, **2020**, 140, 943-947	0	1
15	Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. *Human Molecular Genetics*, **2021**,	5.6	1
14	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. *Heart Failure Reviews*, **2021**, 1	5	1
13	Metainflammation in COVID-19.. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2022**,	2.2	1
12	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2022**, 15, 281-295	3.4	7
11	SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.. *Current Cardiology Reports*, **2022**, 24, 183	4.2	1
10	The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists. *Kachestvennaya Klinicheskaya Praktika*, **2022**, 4-15	0.4	
9	Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2022**, 15, 685-694	3.4	

8	Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.. *Korean Journal of Internal Medicine*, **2022**,	2.5	0
7	Diabetic kidney disease in children and adolescents: an update.. *Pediatric Nephrology*, **2021**, 1	3.2	0
6	Precision Medicine Approaches for Management of Type 2 Diabetes. **2022**, 1-52		
5	Sodium-glucose cotransporter 2-associated perioperative ketoacidosis: a protocol for SAPKA systematic review.		
4	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. *Journal of Diabetes Investigation*,	3.9	0
3	Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs.		0
2	Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. **2023**, 38, 25-33		0
1	A drug utilisation pattern in non-dialysis patients of diabetic nephropathy in a government-run tertiary care hospital in South-Asia. **2023**,		0